



## M. INITIAL CLINICAL TRIAL AND IMPORT LICENSE APPLICATION UNDER REGULATORY RELIANCE

The CTA is granted to Sponsor, Clinical Research Organization and/or Principal Investigator to conduct a clinical trial of an investigational drug product. On the other hand, the IL is granted to Sponsor, Clinical Research Organization and/or Principal Investigator to allow importation of investigational product and ancillary supplies necessary for the conduct of clinical trial. The Philippine FDA recognizes the other National Regulatory Authority decision in the issuance of CT approval based on the criteria set under FDA Circular 2023-004.

Center/Office/Division :	Center for Drug Regulation and Research			
Classification :	Highly Technical			
Type of Transaction :	G2B – Government-to-Businesses			
Who May Avail	: All Sponsors, Contract Research Organizations (CROs), Principal Investigators and Importers			
Fees to be Paid :	of Pharmaceutical Products  be Paid  : AO 50 s. 2001 & FDA Circular No. 2012-007-A : Php 2,500.00 + 1% LRF  Fee for External Regulatory Reviewers: Php 60,000.00  Import License for Clinical Study: Php 500.00/importation + 1% LRF			
	CHECKLIST OF REQUIREMENTS	WHERE TO SECURE		
AO No. 2020-0010: Regulations on the Conduct of Clinical Trials for Investigational Products Initial Clinical Trial & Import License Application Requirements  1. Table of Contents for Clinical Trial Application 2. Cover Letter for Application 3. Clinical Trial Application Form 4. Investigational Product and Ancillary Supplies Information 5. Import License Application 6. Proof of payment 7. Letter of Authorization 8. Clinical Trial Protocol and amendment(s), where applicable 9. GCP Certificate and Curriculum vitae (CV) for investigators of each trial site 10. Informed Consent Form/Assent Form 11. Investigator's Brochure 12. Pharmaceutical Data 13. GMP Certificate from NRA and/or evidence of GMP compliance				





- 14. Shipping condition for IP and trial related materials
- 15. Labelling Materials of the Investigational product

Additional requirements based on FDA Circular 2023-004

- 16. A formal letter written request from the applicant notifying the FDA of its intent to avail of the abridged review, identifying the RDRA.
- 17. Copy of the clinical trial approval or any equivalent from the identified RDRA. Proof of conduct of the clinical trial in the country of RDRA such as clinical trial registry.
- 18. A Sworn Assurance duly signed by the Sponsor or the authorized CRO stating the requirements under Section V.A.7.b and A.7.c of the Circular

CLIENT STEPS	AGENCY ACTION	FEES TO BE PAID	PROCESSING TIME	PERSON RESPONSIBLE
E-mail submission: Submits the application for preassessment through clinicalresearch@fda.gov.p h.	1. Pre-assesses the completeness of the application. If the application is acceptable, informs the client of the result of the preassessment, issue the Document Tracking Number (DTN), and instructs the client to proceed with the payment. If the application did not satisfactorily pass the pre-assessment, inform the client of the deficiency/ies.	None		CRS Administrative Staff
<ul> <li>2. For accepted applications, pays the required fee through any of the following:</li> <li>FDA Cashier</li> <li>BANCNET</li> <li>Landbank OnColl</li> <li>Sends proof of payment to Clinical Research Section</li> </ul>	Upon receipt of the proof of payment, the application will be encoded/update in the database.	AO 50 s. 2001 & FDA Circular No. 2012-007-A: Php 2,500.00 + 1% LRF Import License for Clinical	Day 1 1 working day	CRS Administrative Staff





through clinicalresearch@fda.gov.ph	Decks/Assigns the application to an evaluator.	Study: Php 500.00/imp ortation + 1% LRF	Day 1 1 working day	Food-Drug Regulation Officer (FDRO) III
	3. Evaluates the application for completeness and scientific worth *Any minor deficiencies/ clarifications will be communicated to the clients through electronic communication (3 working days to respond to the queries)	None	Day 1 1 working day	Food-Drug Regulation Officer (FDRO) I/II (Junior Evaluator)/ FDRO III (Senior Evaluator)
	Assigns regulatory reviewer /issuance of regulatory permit	None	Day 2 1 working day	FDRO I/II/III
	5. Forwards documents (Protocol and other documents) to External Regulatory Reviewer	None	Day 2 1 working day	Applicant
	6. Reviews Pharmaceutical data requirements and Import License application	None	Day 3-17 15 working days	FDRO I/II/III
If an electronic notice of deficiencies (E-NOD) was issued by the external regulatory reviewer, submits complete compliance documents to the evaluator.	7. Assesses the application though the FDA CT Assessment Form *Any clarifications/ deficiencies will be communicated to the clients through electronic communication (10 calendar days to respond to the queries)	Fee for External Regulatory Reviewers: Php 60,000.00 (direct to External reviewers) FDA	15 working	External Regulatory reviewer [St. Luke's Medical Center (SLMC),





*This constitutes a stop clock on the processing time (based on AO 2020- 0010, Section VI, Paragraph 5.6)			University of the Philippines  - National Institutes of Health (UPNIH), Philippine Heart Center (PHC)]
Reviews the assessment from the Regulatory Reviewer	None	Day 17 1 working day	FDRO I/II/III
Reviews the evaluated application bearing the recommendation of the evaluator	None	Day 18 1 working day	Clinical Research Section Supervisor
10. Prints the final response and forwards it to the Product Research and Standards Development Division (PRSDD) Chief	None	Day 19 1 working day	FDRO I/II/III
11. Checks and recommends the decision of the evaluator/s by affixing initial/signature	None	Day 19 1 working day (per batch of applications)	PRSDD Chief
12. Signs and approves the final decision	None	Day 19 1 working day (per batch of applications)	CDRR Director
13. Encodes/Updates the Database and Endorses the final output document to the AFS Releasing Section	None	Day 20 1 working day (per batch of applications)	CDRR-CRR Unit Personnel





	TOTAL: Service is covered under Administrative Order No. 2020-0010.		PHP 63,035.00	20 Working day	/s
		and IL to the client	None	1 working day	Section Personnel
Ī	3. Receives the approval	14. Releases the appropriate CT response		Day 20	AFS Releasing